Transparency in Program Selection

Introduction

Choosing a transplant program (transplant program selection) is a decision with important implications for patients’ chances to successfully complete the evaluation process, be waitlisted for an organ, and ultimately receive a transplant. In the United States, research shows that many patients consider multiple programs, and may choose programs far from their home, or pursue listing at multiple programs. Patient acceptance criteria, waiting time, and mortality vary significantly by program, underscoring the importance of transparency about factors which may influence program selection.

Disparities in access to transplant remain, including disparities by age, clinical presentation, body mass index (BMI), and race. Disparities in access to care may be exacerbated by a lack of public information about transplant programs’ listing practices. For example, patients may be unaware of differing BMI thresholds, abstinence requirements for substance use, social support requirements, and financial requirements between programs. This can be particularly problematic for patients for whom insurance will only cover one evaluation and who find out during the evaluation process that they will not be listed at a given program because of one of these factors. Even patients who are ultimately listed may benefit from knowing this information earlier. Patients are often unaware of the impact that differences in program-specific acceptance criteria, waiting times, and mortality rates can have on their likelihood of being waitlisted and receiving a transplant. Challenges persist in understanding how quickly patients will be placed on the waitlist, and the likelihood that they would be deemed an acceptable candidate for a particular program based on their physical, medical, or social characteristics. Lack of access to data about patient evaluation and listing practices limits the ability to make informed choices about where to seek care.

---

1 OPTN Policy 1.2 Definitions defines transplant program as “A component within a transplant hospital that provides transplantation of a particular type of organ.”


In light of these challenges and persistent disparities, there is an urgent need to increase patient access to pre-transplant referral and evaluation information. To this end, this white paper examines the principles of disclosure in transplantation and considers examples where transparency of pre-listing information supports equitable and patient-centered access to transplantation.

**Review of Relevant Literature**

A systematic literature review was conducted to identify information that patients (transplant candidates, transplant recipients, transplant support persons, or living donors) believe is relevant to the selection of a transplant program. During this literature review, information that transplant professionals thought would be useful for patients was also identified.

Table 1-1 provides further details about the literature review screening process and the identified sources. Supplemental information on the literature review and article selection process can be found in Tables 1-2 and 1-3 of Appendix 1.

Through the analysis, 17 articles were identified that report data about content desired by patients or suggested by professionals. While most of the articles focus on the kidney transplant population, a few include patients or transplant professionals of other organ types. However, data was not available on patients awaiting intestine, lung, or pancreas transplant. To summarize the findings, the desired information fell into six main categories: general information about the transplant program or staff, referral and evaluation, waitlisting, transplant and perioperative outcomes, long-term follow up and outcomes, and living donation.

Table 1-1 provides details about the subtopics of information desired within each of the six major categories. Patients wanted more information about the experiences that patients who had similar demographic or disease characteristics as themselves had at a transplant program, in addition to more general data about volume and outcomes. Of note, many topics that patients wanted to learn more about are areas where data is not currently included in the Scientific Registry of Transplant Recipients (SRTR) program reports (e.g. patient-reported outcomes).

---


13 See Appendix 1.

14 Brett, “Perspective.”


23 Schaffhausen, “How patients.”

24 Schaffhausen, “Comparing.”

25 Schaffhausen, “Tool.”
including quality of life and patient satisfaction).\textsuperscript{26} Furthermore, some professionals assert that not all of the desired topics are easily assessed or compared (e.g. continuity of providers throughout the transplant process).\textsuperscript{27,28,29,30} While this literature has provided a better understanding of what information is important to patients and transplant professionals, it also expounded on the need for more transparent, consistent, and patient-friendly information to improve shared decision-making.

**Ethical Principles**

Autonomy, procedural justice, equity, and utility are critical principles to guide the recommendations as to what types of information patients should be aware of when making decisions about where and how to seek transplant care.\textsuperscript{31}

**Autonomy**

The principle of autonomy refers to one’s ability to be self-directing, have a decisive impact on what happens to oneself in the future, and, in terms of transplantation, and participate in decisions that lead to medical treatment, including program selection. The principle of autonomy is also associated with respect for persons, i.e., the notion that patients should be treated in a way that facilitates choice and that preserves dignity. Finally, autonomy holds that actions or practices tend to be right insofar as they support individuals’ independent choices, as long as the choices do not impose harm to others.\textsuperscript{32,33} The accessibility and clear presentation of information relevant to medical decision-making are critical to support patients’ ability to exercise their autonomy. Therefore, autonomy justifies the disclosure of program-specific information relevant to transplant program selection and shared decision-making.\textsuperscript{34}

**Procedural Justice**

Procedural justice upholds a commitment to treating like cases similarly, transparently, and predictably. Procedural justice pertains to transparency in program selection in two primary respects: 1) public accessibility of listing decisions and the rationale for making these decisions, and 2) all justifications of decisions should rely on rationales that are reasonable and appeal “to evidence, reasons, and principles that are accepted as relevant by fair-minded people.”\textsuperscript{35,36}

---

\textsuperscript{26} Scientific Registry of Transplant Recipients, “Program-Specific Reports,” accessed June 4, 2022, https://srtr.org/reports/program-specific-reports/.


\textsuperscript{32} Ibid.

\textsuperscript{33} Tom L Beauchamp and James F. Childress, Principles of Biomedical Ethics 4th edition (Oxford: Oxford University Press, 1994).


While the exact content of what information procedural justice requires remains somewhat open, in the context of organ transplantation, it is important for there to be greater symmetry of information between patients and clinicians about features of transplant program evaluation, waitlisting, and transplant that could affect a patient’s decision to pursue transplant at a given program. The OPTN maintains, “procedural justice is critical to preserving public trust and participation in the transplant system, as it ensures that all patients in need will receive similar treatment.”

Procedural justice also requires that patients have access to the reasons underlying each decision that affects access to transplant, such as the decision to register a patient for the waitlist (or not), and to make a patient inactive (or not). Procedural justice does not require every program to provide the same services or approach, but instead, to provide consistent information on what is available, factors impacting patient success, and the program’s approach for patient decision-making. Transparency of information relevant to transplant program selection allows for the transplant listing process to be evaluated for fairness and consistency, facilitates a patient’s ability to hold a program accountable, and enhances trust in the system.

Equity

The principle of equity refers to removing structural barriers to accessing transplantation and mitigating undue disadvantage experienced by those who come from structurally marginalized communities or have fewer resources. The principle of equity invokes a commitment to health equity by focusing on reducing health disparities commonly defined as the “systematic, plausibly avoidable health differences adversely affecting social disadvantaged group” such as “race or ethnic group, skin color, religion, language, or nationality; socioeconomic resources or position; gender, sexual orientation, or gender identity; age, physical, mental or emotional disability or illness, geography, political or other affiliation; or other characteristics.” Asymmetry of information may worsen outcomes for structurally marginalized patients, further exacerbating disparities, such as the lack of awareness and differential use of race as a coefficient in the glomerular filtration rate (GFR) for Black patients with kidney disease. The lack of accessible information about transplant program listing practices may disproportionately affect these populations, including those who may be disqualified due to nonmedical criteria. Transparency of program information facilitates equity in patient access – such as when insurance policies pay for only one transplant evaluation, a common logistical and financial constraint. Even when insurance may cover multiple evaluations, patients and families incur costs and burdens, including those associated with co-pays, transportation, missed work, and dependent care, among others. When relevant information is available in a clear and timely manner, it lessens the burden on

40 During the June 2022 OPTN Board of Directors meeting, the Board approved changes to OPTN policy to disallow the use of race-inclusive eGFR calculators for OPTN purposes.
43 Ibid.
patients to self-educate. Self-education is more challenging when patients have fewer resources and lack access to resources.

Utility

Finally, the principle of utility, which in the context of organ allocation refers to the maximization of net benefit (including promoting graft survival, reducing waste, and improving efficiency), may also justify greater transparency in listing practice, although this remains an open empirical question.  For example, increasing disclosure of relevant information could lead patients pursuing transplantation to more rapidly identify a program that fits their needs, thus reducing health care expenditures arising from multiple waitlist evaluations. Without this, patients may engage in duplicate testing and evaluations after being predictably turned away from a given program owing to failure to disclose and explain relevant data. Conversely, transparency of information, clarity of communication, and shared decision-making are conducive to efficient treatment and increased attention to the patient perspective. However, it is possible that transparency in transplant listing criteria may negatively impact utility, for example, if greater requirements for transparency and disclosure were to negatively influence transplant programs to be more defensive or conservative. We will address this exception below. Traditionally, the organ transplant field considers utility related to organ allocation, but utility also applies to patient optimization of transplant options. Although this white paper demonstrates how utility may be positively impacted, further research here is needed.

Complicating Questions

Having addressed ethical principles that underlie the need to enhance the accessibility of data to inform decisions about where to pursue transplant, the below provides four examples of potential negative consequences that may arise from increased access to information, specifically data, which require further exploration.

Unintended Consequences of Publishing Data

First, should data be published if doing so might have the unintended consequence of decreasing programs’ willingness to transplant patients whose outcomes they fear may affect other patients or referring physicians’ perceptions of the program? The “cherry-picking” concern here is that an increase in publicized data might negatively influence transplant programs to engage in defensive patient selection practices, thus diminishing patients’ ability to choose a transplant program. Similar concerns were previously raised about the implementation of “report cards,” a concern which ultimately proved unfounded, in part due to limited patient use of the data.

---

45 Ethical Principles in the Allocation of Human Organs defines “the principle of utility, applied to the allocation of organs, thus specifies that allocation should maximize the expected net amount of overall good (that is, good adjusted for accompanying harms), thereby incorporating the principle of beneficence (do good) and the principle of non-maleficence (do no harm).” https://optn.transplant.hrsa.gov/professionals/by-topic/ethical-considerations/ethical-principles-in-the-allocation-of-human-organs/.
If public reporting contributes adversely to the cherry-picking of patients, prioritizing those most likely to be predicted to have good outcomes, it may undermine equity and utility. This underscores the critical task of determining not only what data are relevant to disclose, but also how these may be appropriately risk-adjusted and presented predictably and consistently across various transplant programs. Nonetheless, empirical challenges to appropriately risk adjust should not impede efforts to promote autonomy and equity.

Perhaps much of the concern about the unintended consequences of publishing data can be allayed by considering the distinction between the terms “data” and “metrics.” Data are quantitative information, not value judgments. Metrics, by contrast, are “measures that have been developed to support self-assessment and quality improvement at the provider, hospital and/or health care system level.” In light of the distinction between these two terms, it is critical to emphasize that the recommendations rooted in this principles-based analysis concern the disclosure of data, not the advocacy of which metrics to utilize. It is also important to acknowledge that making a distinction between “data” and “metrics” is not to suggest that data are in all cases neutral. The selection of which data to scrutinize and publicize, and how to frame these strategic decisions, are admittedly values-based decisions, ultimately affecting the overall interpretation of data. In this case, access to data that could be understood and used by patients to decide where and how to seek care that aligns with their values is at the core of autonomy and shared decision-making. To support this, there is a need for transplant programs to provide information, including data, to patients during the pre-listing stage, the period of transplantation at which data sharing and transparency is most conspicuously lacking.

Disclosure and Paternalism

Second, what should be done in cases where patients are not necessarily interested in data, but the referring clinician or transplant professional thinks the data may help the patient in their transplant program decision? For example, transplant professionals might view the organ acceptance rate ratio as relevant data even if patients have not yet requested this information. Considerations like this, in turn, lead to a more fundamental question: is the appropriate data collected to benefit the patient? Information and data that is disclosed should be done so in a manner that is consistent with promoting patients’ interests.

Regarding potential concerns about paternalism, rather than immediately deciding that particular information should not be provided, transplant professionals should engage in a discussion with patients to determine what information would be meaningful to them as well as how to interpret the information and its potential impact. It may turn out that this is a case in which paternalism stands in tension with autonomy, where providing patients too much information, or information that is not relevant or useful, may hinder their decision-making process and impede shared decision-making. Just as a patient can feel paralyzed in confronting an illness when presented with too many options, so could the act of over-informing render an already onerous process even more overwhelming. Thus, it is important to acknowledge that there are reasonable limits to disclosure and transparency. In keeping

52 Brett, “Perspectives.”
with the principle of autonomy described above, this type of extraneous information should be determined in advance and should remain unshared in a manner which is consistent and non-discriminatory (despite that it also may not be completely uniform). This is a question of balance, calling attention to the importance of engaging patient stakeholders in the process of identifying the information that they find the most useful to select a program and to increase transparency, which may also elucidate barriers and facilitators of early access to transplant, or delineate the impact of varied experiences at the referral and evaluation stages of transplantation.

Potential Misinterpretations in Disclosure

Third, conversely related to the issue of paternalism, are there circumstances where it is ethical to withhold information when there is evidence (or merely concern) that patients may misinterpret the data, potentially adding to their anxiety or inducing them to make decisions that do not optimize their chance to receive a transplant?

When disclosing any information, it is always important to consider the possibility that data can be misinterpreted. If there is a concern that patients are misinterpreting data, the first step should be an assessment of the reason(s) for the misunderstanding. Does the confusion arise from how the data are presented? Is the patient receiving conflicting information from other sources? Does the patient lack comprehension of how the data apply to them? Widespread, persistent misinterpretations of data could have a negative effect on patients and should lead to a systematic effort to consider how the data are defined, collected, publicly presented, described, and portrayed.

In other words, rather than withholding information because of concerns about how it might be interpreted, it is better to offer educational resources which aid interpretation. There still may be valid exceptions to disclosure, but these could be addressed on a case-by-case basis, with specific reasons proffered when information is withheld. In keeping with a patient-centered approach to transparency, it is imperative that the public understands both what is shared and, in exceptional cases, the process by which certain data are determined to remain exclusive.

Access and Transparency

Many patients who seek transplant do not have the option to select their transplant center. This can be due to geographic considerations, constraints placed by insurance coverage, limitations due to medical characteristics, or socioeconomic factors. One concern is that patients with these constraints will lack the ability to take advantage of enhanced informational transparency, while those with greater resources will be able to “shop around” for programs. This has the potential to increase inequities in the transplant system.

Increased transparency cannot rectify all the systemic inequities and disparities that affect our healthcare system and society. It is relevant to note that no patient will be made worse off, in an absolute sense, as a result of enhanced informational transparency. In fact, increased transparency will likely benefit at least some patients who currently have constrained options. For example, if only a single transplant evaluation is covered by insurance, access to additional information can help a patient and referring physician identify the center that is the most likely to meet their needs. In addition, if a patient’s candidacy is denied, increased transparency will help them identify the best alternative center from which to seek a second opinion. Increasing transparency should be viewed as a step toward “levelling-up” all patients.53 This “levelling-up” will achieve the ultimate goal of efficiently matching all

patients to the program that is best suited for the patient’s needs. Ideally, this efficient matching will ultimately reduce patients’ wait time and optimize post-transplant outcomes.

**Experiential Examples of Transparency**

The ethical principles described above support the disclosure of additional information that may be helpful to patients when selecting a transplant program. This white paper presents five examples in which patients might seek greater clarity and transparency during the pre-evaluation phase. Collectively, these examples demonstrate how information that comprehensively addresses a variety of medical characteristics can inform transplant evaluations, thereby impacting imminent decision-making. Transparency is justified within each example by appealing to autonomy, procedural justice, equity, and utility as detailed above.

Although this white paper focuses on these representative conditions, which reflect many patients seeking transplantation, this is not an exhaustive list. A discussion of concrete examples illustrating the ethical justifications supports ease of understanding for a diverse readership. The patient-facing data suggested in each example are meant to be illustrative, not exhaustively inclusive. They are not meant to be comprehensive of all patient experiences, nor do they dictate medical practice to transplant programs.

**Example 1: Alcohol Use**

Liver transplant patients may struggle to identify programs available to them before initiating evaluation and may need information about how selection criteria impact access to transplant, as well as information specific to their medical characteristics, both of which inform decision-making. Patients with end-stage liver disease with a recent history of alcohol use could be concerned about their perceived fitness for referral. This subset of patients may ask the question: “If I were to be evaluated for transplant, how likely is it that I would be waitlisted at that program? What are the requirements, if any, about abstinence periods?” Information regarding the steps for physician referral and self-referral promotes autonomy by allowing the patient to search for programs that would accept them for pre-transplant evaluation despite recent alcohol use while excluding programs that disqualify patients before evaluation due to recent alcohol use. If a patient were informed of a required abstinence period prior to evaluation, they would be able to more adequately consider their options prior to utilizing their insurance and other out-of-pocket expenses. This underscores the importance of bi-directional communication prior to the evaluation process, where a patient becomes aware of clear expectations for what might be required to move a process forward and possibly given resources with which to do so.

---

54 Schaffhausen, “Comparing.”
55 Ibid.
57 Ibid.
Example 2: Obesity

Obese patients may face challenges in trying to understand a particular program’s listing practices for patients based on high BMI if data are not publicly available, an issue that is exacerbated because obese patients often face longer time on the waitlist because of their weight. 60

Data show that 21% of kidney transplant programs do not list any patients with BMI greater than 40 kg/m², and 15% do not list patients with BMI greater than 35 kg/m². 61 The median time to transplant for patients with kidney disease and a BMI greater than or equal to 35 kg/m² is 10 months longer than for patients with a BMI below 30. 62 Improved transparency about BMI criteria and time to transplant for patients with high BMI presents substantial opportunities for improving equity in access. Sharing information about why BMI matters more at a particular transplant program and why the program sets a BMI threshold will include obese patients in the process of selecting an appropriate transplant program, leading to an increase in access for these patients (upholding equity). A patient’s likelihood to have a successful transplant may depend on having some knowledge of the program’s record of getting people transplanted who entered the evaluation with a high BMI.

Patients with higher BMIs might benefit from understanding which approaches a program takes to waitlisting status while they attempt to lose weight to achieve a target BMI. They may also wonder what resources are available at programs to help them achieve weight loss and meet the program’s stated target. Patients may seek to know which programs offer sleeve gastrectomy in combination with transplant or robotic-assisted kidney transplant, which show good outcomes for obese patients. 63 Providing the program’s BMI cut-off would be more patient-friendly and informative than requiring patients to search through outcome data to inform their decision.

To summarize, the principle of autonomy supports publicizing criteria that programs use in deciding whether to list patients who are obese, how obesity affects time on the waitlist, and what the outcomes are for obese patients compared to non-obese patients. Autonomy and equity would be served by a uniform approach to presenting this information accessibly and in a way that does not reduce access for people because of their weight, but provides information on the rationale for placing limits on BMI. 64

Example 3: Potentially Frail Patients

Organ transplants are rigorous procedures under the best of circumstances, with lung transplants reporting 1-and 5-year survival of 85% and 59%, respectively, since 2010. 65 Patients that have increased vulnerability to adverse outcomes or decreased capacity to tolerate stressors may be considered higher risk. 66 Patients may want to know what additional considerations programs take when deciding who has the physical capacity to undergo surgery and who is too frail. Frailty is a clinical syndrome, and currently,
there is no consensus about standards for defining it.\textsuperscript{67,68} Patient awareness of their characteristics that might lead transplant programs to consider them frail, and knowledge of how a program might evaluate them for suitability, would allow patients to make wiser choices about evaluation. For example, a patient with diabetes and below the knee amputation may be limited in their ability to perform a timed walk test, which is a common test in a transplant evaluation, but may meet other criteria for robustness.\textsuperscript{69} Patients may also learn whether transplant programs have services to help them increase endurance.\textsuperscript{70}

Frail individuals may experience decreased pain tolerance and additional physical trauma from surgical complications. They may ask: “What resources are available for patients like me at this transplant program?” Pain management and special attention to this patient population (such as providing access to pre-habilitation services and anticipating potential complications) will lead to more frail patients being eligible for transplant, in turn, leading to greater utility.\textsuperscript{71}

Patients who may meet one or more of a programs’ criteria for frailty would have an interest in knowing if a transplant program offers pre-habilitation services to enhance functional capacity prior to surgery.\textsuperscript{72} As an alternative to being declined for transplant completely, these patients might benefit from being made aware of plans for improving their strength and nutrition and what risk factors that might cause a program to move a patient to inactive status or off the waitlist entirely.

Finally, frail patients may have a tougher time rehabilitating or tolerating prescribed post-transplant drug regimens and therefore derive greater utility from the transparency of information regarding program standards for management and communication after a surgical procedure. Beyond 1-year and 3-year patient and graft survival, these patients may seek information on other factors that significantly influence their experienced quality of life, such as oxygen dependence, chronic lung allograft dysfunction, and the chance of returning home (as opposed to a rehabilitation or skilled nursing facility) post-transplant.\textsuperscript{73,74}

\textit{Example 4: Highly Sensitized}

Approximately 35\% of patients waitlisted for a kidney transplant are sensitized to human leukocyte antigens (HLA), which increases their chances of acute rejection after transplant and decreases the number of individuals who can donate to them.\textsuperscript{75} Highly sensitized patients can expect longer times on the waitlist and may require multiple evaluations with potential living donors due to cross-match incompatibility.\textsuperscript{76}


\textsuperscript{71} McAdams-DeMarco, “Perceptions.”


\textsuperscript{75} Ibid.
Highly sensitized patients would arguably benefit from additional data about transplant program structure that may not be as relevant to less sensitized patients. Transplant programs that incorporate paired exchange programs or provide intravenous immune globulin (IVIG) therapy may be preferable to the highly sensitized patient who otherwise may rely solely on the deceased donor allocation system. Since highly sensitized patients often require more potential living donor evaluations to find a good match, they may want to know a program’s policy about evaluating multiple potential donors simultaneously or benefit from additional data about living donation. They may wonder: “does the program have donor recruitment coaching or assistance in starting a living donor chain?” These patients may also benefit from understanding the roles of program staff who are dedicated to living donor services. Hypothesis Because immunosuppressive and desensitization therapies increase the risk of complications like infection, highly sensitized patients may have a greater need for access to longer-term program outcomes beyond the 1-year and 3-year benchmarks.

Information about donor selection criteria and outcomes may be relevant for a patient who already has a potential donor in mind. The autonomy of both the donor and the patient must be respected without marginalizing the desires of either. The donor, who is a healthy altruistic individual voluntarily submitting to an extensive battery of tests prior to a substantial surgical procedure, is understandably warranted in wanting to seek a clear understanding of the workup, para-surgical, and follow up processes required by the program. Transparency in information regarding these two related, yet distinct, protocols enhance procedural justice for the donor-recipient pair. Autonomy is also restricted when patients are relegated to choosing a transplant program based on limited information.

**Example 5: Pediatric Living Donor Liver Transplantation**

Pediatric patients are especially vulnerable in their inability to exercise absolute autonomy, instead having to rely on the decision-making of their legal guardian to determine their opportunities for care. Hypothesis The caregiver’s decision to undergo evaluation at a particular center is exceptionally important given the limited number of pediatric transplant programs available. Additionally, many pediatric transplant centers are low volume performers in comparison to adult transplant centers. As a result, low volume centers are faced with balancing acceptable risk tolerance with maintaining optimal outcomes, which could impact their organ acceptance practices. When compounded with the necessity to size match organs to pediatrics, this can severely limit the potential pool of donor organs and affect a pediatric candidate’s equitable access to transplant.

In an attempt to mitigate some of the equity challenges, a pediatric patient seeking a liver transplant may benefit from knowing if a particular center performs living donor liver transplants. This is highly relevant for pediatric patients, given the need to size-match organs between the donor and

---


79 OPTN Ethics Committee, *Revise*.


recipient. Caregivers need to be informed that differences in the center and surgical expertise can expand the donor pool for pediatric candidates. This information will provide caregivers with a greater ability to make informed decisions for their pediatric candidate. Given the organ longevity needed and the necessity for long-term outcomes, including quality of life, transplant center selection is of the utmost importance to pediatric patients and their caregivers. As the ethical principles outlined above are not able to be applied in the same manner to pediatric patients, it becomes critically important for transparent, center-specific information to be provided to this already vulnerable population in order to protect their interests and needs.

**Accessing versus Understanding Information**

Equitable access to information is essential to ensuring transparency in program selection. However, merely making information available, and not ensuring that information is usable, understandable, and accessible to patients will fall short of the goals of protecting patient autonomy and improving equity. Even if relevant information is available, some patients may have barriers to accessing it or may find the information challenging to navigate. Patients who can access the information may face difficulties understanding it or may be overwhelmed by the scope of information. The process is further complicated by the fact that pre-transplant concerns will vary depending on whether the person seeking information is the patient, a potential living donor, or a member of a patient’s social support network.

While optimal health communication poses an important and persistent challenge for public health agencies and clinicians (and one where guidance is beyond the scope of this paper), this white paper briefly notes a few issues that must be addressed to achieve the goal of increased transparency in line with the ethical principles outlined above.

**Reliance on Internet for Information Availability**

Three overwhelming issues arise when relying on the internet (Worldwide Web) for information: infrequent internet access, inadequate digital literacy necessary to inform their decisions, and insufficient health literacy. The digital information available may not sufficiently inform a patient about how best to pursue a transplant. The U.S. Department of Education estimates that 16% of American

---


84 Elisofon, “Society.”


88 OPTN Ethics Committee, *Revise*.


90 Schaffhausen, “The importance.”


adults are not digitally literate.\textsuperscript{93,94} Digital illiteracy is higher in Black (22%), Hispanic (35%), and advanced age population (28% in 55-65 years old), which are all groups disproportionately represented on the waitlist.\textsuperscript{95,96} When a patient is required to rely on technology, which assumes access and digital literacy to find information on which to make decisions, inadequate internet access and computer ability impede upon one’s autonomy and ability to make well-informed decisions for their health. Health literacy poses a second concern. Health literacy is defined by the National Institutes of Health (NIH) as “the degree to which individuals have the ability to find, understand, and use information and services to inform health-related decisions and actions for themselves and others.”\textsuperscript{97} The current system relies on digital literacy to facilitate health literacy but falls short in meeting the needs of the patient. Low health literacy has been associated with lower rates of referral to transplant evaluation.\textsuperscript{98} Steps can be taken to mitigate these inequities to access. For example, a national service that telephonically provides selection support independent of professional relationships and standard referral patterns\textsuperscript{99} could enhance autonomy and provide utility to patients regardless of structural barriers and health literacy.

\textit{Accessibility of Information:}

Equity is furthered by increasing opportunity to access information, not just for people with equipment, skills, and ability to understand it. Further, resources should be accessible for patients with visual or hearing impairments, non-native English speakers, and those with limited health or digital literacy. Information should support autonomy for all, including persons who do not have access to a smartphone or computer or lack access or functional skills adequate to explore online databases and materials.

Information written for a clinical audience that is not appropriately adapted for patients limits the proportion of patients that can incorporate the data into their decision-making process. Further, there is often a disconnect between patient preferences for information and what providers think patients want.\textsuperscript{100} Patient-centered design techniques, including patient co-ownership of the development process at each stage and iterative refinement with the patient, can avoid user-related design errors that impede access and dissemination of transplant program information.\textsuperscript{101}


\textsuperscript{94} The above report defines “not digitally literate” through the PIAAC requirements for determining basic computer competence: “(1) prior computer use, (2) willingness to take the assessment on the computer, and (3) passing a basic computer test (by successfully completing four of the six simple tasks, such as using a mouse and highlighting text on the screen.”

\textsuperscript{95} U.S Department of Education, “A Description.”

\textsuperscript{96} Park, “A scoping.”


Conclusion

This white paper concludes that principles of autonomy, equity, utility, and procedural justice strongly support increasing patient access to pre-waitlist data and information about the transplant evaluation process and waitlisting decisions. These principles are core to the organ transplant system and imperative to maintain an ethical system of allocation.\textsuperscript{102} Transparent data that contribute to patients’ ability to be waitlisted is necessary for ensuring equitable access to care while supporting patient autonomy and utility. Greater transparency about pre-listing information can help patients find programs that are the best fit for their health needs, values, and preferences. This white paper supports transparency and accountability within the transplant system through an ethical analysis that lays the foundation for future improvements.

\textsuperscript{102} OPTN Ethics Committee, \textit{Ethical Principles}. 
<table>
<thead>
<tr>
<th>Types of Information desired by phase of transplant process</th>
<th>Who the information is desired by and what literature it was found in</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General center data</strong></td>
<td></td>
</tr>
<tr>
<td>Center years performing transplant</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Clinical practice differences from other centers</td>
<td>Professionals (Gordon 2013)</td>
</tr>
<tr>
<td>Continuity of providers throughout transplant process</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Distance from home</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Outreach or support program</td>
<td>Patients (Husain 2018, Schaffhausen 2019)</td>
</tr>
<tr>
<td>Participation in research or innovation</td>
<td>Patients (Schaffhausen, 2019)</td>
</tr>
<tr>
<td>Reputation</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Risk tolerance of the center</td>
<td>Professionals (Gordon 2013)</td>
</tr>
<tr>
<td>Staff &amp; surgeon training</td>
<td>Patients (Husain 2018, Schaffhausen 2019)</td>
</tr>
<tr>
<td>Teaching institution</td>
<td>Patients (Husain 2018, Schaffhausen 2019)</td>
</tr>
<tr>
<td><strong>Referral</strong></td>
<td></td>
</tr>
<tr>
<td>Citizenship status of candidate donor or recipient</td>
<td>Patients (Schaffhausen 2017)</td>
</tr>
<tr>
<td>Cost of pre-transplant evaluation</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Insurance accepted</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Multiple/alternative center listing for transplant</td>
<td>Patients (Schaffhausen 2017, Crenesse-Covien 2019, Schaffhausen 2019, Schaffhausen 2020)</td>
</tr>
<tr>
<td>Patient qualifications for transplant</td>
<td>Patients (Schaffhausen 2017, Schaffhausen 2019)</td>
</tr>
<tr>
<td>Quality of life among referred patients</td>
<td>Professionals (van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Second opinion evaluations</td>
<td>Patients (Schaffhausen 2017)</td>
</tr>
<tr>
<td>Waitlisting rate (ratio of patients who are waitlisted relative to the person-years referred for evaluation) / ease of getting waitlisted</td>
<td>Patients (Schaffhausen 2017, Husain 2018) Professionals (Paul 2021)</td>
</tr>
<tr>
<td><strong>Waitlisting</strong></td>
<td></td>
</tr>
<tr>
<td>Health status changes for waitlisted patients</td>
<td>Professionals (Brett 2018)</td>
</tr>
<tr>
<td>Organ acceptance, high-risk organs</td>
<td>Patients (Schaffhausen 2017, Schaffhausen 2019)</td>
</tr>
<tr>
<td>Quality of life among waitlisted patients</td>
<td>Professionals (van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Types of Information desired by phase of transplant process</td>
<td>Who the information is desired by and what literature it was found in</td>
</tr>
<tr>
<td>-----------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Time on waiting list / time to transplant</td>
<td>Patients (Schaffhausen 2017, Husain 2018, Schaffhausen 2019)</td>
</tr>
<tr>
<td></td>
<td>Professionals (Gordon 2013, van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Transplant rate</td>
<td>Professionals (Sawinski 2018, Schold 2019, Schaffhausen 2020)</td>
</tr>
<tr>
<td></td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Variations in illness severity at time of transplant</td>
<td>Patients (Schaffhausen 2017, Schaffhausen 2020)</td>
</tr>
<tr>
<td>Variations in organ availability</td>
<td>Professionals (Husain 2018)</td>
</tr>
<tr>
<td>Waitlist mortality</td>
<td>Patients (Schaffhausen 2019)</td>
</tr>
<tr>
<td></td>
<td>Professionals (Brett 2018, Schold 2019, van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Transplant</td>
<td></td>
</tr>
<tr>
<td>Cost of procedure</td>
<td>Patients (Schaffhausen 2017, Husain 2018)</td>
</tr>
<tr>
<td>Volume of transplants, overall</td>
<td>Professionals (Gordon 2013, van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td></td>
<td>Patients (Schaffhausen 2017, Husain 2018)</td>
</tr>
<tr>
<td>Volume of transplants, based on donor-specific health characteristics (e.g. increased risk, HCV)</td>
<td>Professionals (McKinney 2020)</td>
</tr>
<tr>
<td></td>
<td>Patients (Schaffhausen 2020)</td>
</tr>
<tr>
<td>Volume of transplants, based on patient-specific health characteristics (e.g. age, BMI)</td>
<td>Patients (Husain 2018, McKinney 2020, Schaffhausen 2017, Schaffhausen 2020)</td>
</tr>
<tr>
<td>Volume of transplants, complex cases</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td>Post-transplant</td>
<td></td>
</tr>
<tr>
<td>Complications &amp; readmissions</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td></td>
<td>Professionals (Brett 2018, van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Functional status of recipients</td>
<td>Professionals (van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Immunosuppression regimen variations</td>
<td>Professionals (Gordon 2013)</td>
</tr>
<tr>
<td>Infectious disease transmission</td>
<td>Professionals (Brett 2018)</td>
</tr>
<tr>
<td>Patient-reported outcomes</td>
<td>Professionals (Schold 2019)</td>
</tr>
<tr>
<td>Patient or graft survival</td>
<td>Patients (Husain 2018, Schaffhausen 2017, Schaffhausen 2019, Schaffhausen 2020)</td>
</tr>
<tr>
<td></td>
<td>Professionals (Gordon 2013, Howard 2006, Schold 2019)</td>
</tr>
<tr>
<td>Post-transplant care expectations and ease</td>
<td>Patients (Husain 2018)</td>
</tr>
<tr>
<td></td>
<td>Professionals (Gordon 2013)</td>
</tr>
<tr>
<td>Post-transplant length of stay</td>
<td>Professionals (Brett 2018, van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Types of Information desired by phase of transplant process</td>
<td>Who the information is desired by and what literature it was found in</td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>Quality of life among transplanted patients</td>
<td>Professionals (van Pilsum Rasmussen 2019)</td>
</tr>
<tr>
<td>Living donor</td>
<td></td>
</tr>
<tr>
<td>Living donor outcomes</td>
<td>Patients (Schaffhausen 2017)</td>
</tr>
</tbody>
</table>

**Table 1-2: Database search terms**

<table>
<thead>
<tr>
<th>Medline (EBSCO)</th>
<th>Question 1: Patient selection of transplant programs</th>
<th>Question 2: Patient selection of transplant programs in Hispanic and African American patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>**356 Results</td>
<td>English Language**</td>
<td>**178 Results</td>
</tr>
<tr>
<td>((TI transplant* OR AB transplant*) N5 (TI center* OR AB center* OR TI program OR AB programs OR TI programs OR AB programs)) AND (MM &quot;Patient Preference&quot; OR MM &quot;Patient Education as Topic&quot; OR MM &quot;Choice Behavior&quot; OR (TI patient-centered OR TI patient-specific OR AB patient-centered OR AB patient-specific OR ((TI patient* OR AB patient* OR TI candidate* OR AB candidate* OR TI recipient* OR AB recipient*) AND (MH &quot;Decision Making&quot;))) OR (TI decision-making OR AB decision-making OR TI decision-support OR AB decision-support OR TI preference* OR AB preference* OR TI perception* OR AB perception*)) AND (LA English) NOT (TI clinical-decision-making OR AB clinical-decision-making)</td>
<td>(MH &quot;Organ Transplantation+&quot; OR MH &quot;Transplant Recipients&quot; OR ((TI transplant* OR AB transplant*) N5 (TI organ OR AB organ OR TI organs OR AB organs OR TI liver* OR AB liver* OR TI kidney* OR AB kidney* OR TI heart* OR AB heart* OR TI lung* OR AB lung* OR TI pancreas OR AB pancreas OR TI center* OR AB center* OR TI program OR AB program OR TI programs OR AB programs OR recipient*)) AND (MM &quot;Patient Preference&quot; OR MM &quot;Patient Education as Topic&quot; OR MM &quot;Choice Behavior&quot; OR (TI patient-centered OR TI patient-specific OR AB patient-centered OR AB patient-specific OR ((TI patient* OR AB patient* OR TI candidate* OR AB candidate* OR TI recipient* OR AB recipient*) AND (MH &quot;Decision Making&quot;))) OR (TI decision-making OR AB decision-making OR TI decision-support OR AB decision-support OR TI preference* OR AB preference* OR TI perception* OR AB perception*))) AND (LA English) NOT (TI clinical-decision-making OR AB clinical-decision-making) AND (MH &quot;Ethnic Groups+&quot; OR MH &quot;Minority Groups+&quot; OR MH &quot;Minority Health+&quot; OR TI african-american* OR AB african-american* OR TI afro-american* OR AB afro-american* OR TI black* OR AB black* OR TI Hispanic* OR AB Hispanic* OR TI Mexican* OR AB Mexican* OR TI latino* OR AB latino* OR TI Latina* OR AB latina* OR TI latinx OR AB latinx OR TI minorit* OR AB minorit* OR TI race OR AB race OR TI racial OR AB racial OR TI ethnic-group* OR AB ethnic-group* OR TI ethnicit* OR AB ethnicit*) AND (LA English)</td>
<td></td>
</tr>
<tr>
<td>Question 1: Patient selection of transplant programs</td>
<td>Question 2: Patient selection of transplant programs in Hispanic and African American patients</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>-------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>PubMed narrow</strong></td>
<td><strong>PubMed narrow</strong></td>
<td></td>
</tr>
<tr>
<td>Exact phrases for transplant centers/programs</td>
<td>Exact phrases for transplant centers/programs/organisms</td>
<td></td>
</tr>
<tr>
<td>368 Results</td>
<td>English Language</td>
<td>277 Results</td>
</tr>
<tr>
<td><strong>PubMed broad</strong></td>
<td><strong>PubMed broad</strong></td>
<td></td>
</tr>
<tr>
<td><strong>These search terms were used.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transplant with center or program in title/abstract</td>
<td>Transplant within title/abstract of organs/programs/centers</td>
<td></td>
</tr>
<tr>
<td>1132 Results</td>
<td>English Language</td>
<td>314 Results</td>
</tr>
</tbody>
</table>
Table 1-3: Article selection flowsheet

All articles (n=1454)
  1137 Query 1
  317 Query 2

Duplicates (n=119)

Abstracts reviewed (n=1335)

Not relevant based on abstract review (n=1123)
  6 No abstract
  362 Not solid organ
  139 Not North America
  68 Donor only
  552 Not relevant to transparency topics

Full text review (n=212)

Not relevant based on full-text review (n=195)
  24 Not North America
  12 Donor only
  154 Not relevant to transparency topics
  4 Not patient, support person, transplant professional perspective
  1 Format but not content of transparency topics

Analyzed (n=17)